Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.
Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.
Bertolotti
Page
P
Cedars-Sinai Outpatient Cancer Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. page.bertolotti@cshs.org
Bilotti
Elizabeth
E
Colson
Kathleen
K
Curran
Kathleen
K
Doss
Deborah
D
Faiman
Beth
B
Gavino
Maria
M
Jenkins
Bonnie
B
Lilleby
Kathy
K
Love
Ginger
G
Mangan
Patricia A
PA
McCullagh
Emily
E
Miceli
Teresa
T
Miller
Kena
K
Rogers
Kathryn
K
Rome
Sandra
S
Sandifer
Stacey
S
Smith
Lisa C
LC
Tariman
Joseph D
JD
Westphal
Jeanne
J
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007857:Leadership; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000451:nursing; D012956:Societies, Nursing
D000970:Antineoplastic Agents